Clinical trials: sponsored by University of Oxford
Scabies
Evaluating Pediatric Ivermectin in Children Under 15 kg (EPIC-15)
The EPIC-15 trial will evaluate the safety, pharmacokinetics, acceptability, and efficacy of pediatric ivermectin (CHILD-IVITAB) in scabies infected children weighing 5 to less than 15 kg.
- Trial name
- EPIC-15 (NCT06404333)
- Testing
- CHILD-IVITAB
- Where
- Brazil
- Volunteers
- 13 people
- Sponsor
- University of Oxford
Muscular Atrophy, Spinal
Newborn Screening for Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is a rare, treatable, genetic disease that typically occurs in infancy and early childhood. SMA progressively, and irreversibly, destroys motor neurons in the brainstem and spinal cord, which control…
- Trial name
- SMA-NBS (NCT05481164)
- Where
- 9 sites in United Kingdom
- Volunteers
- 33,568 people
- Sponsor
- University of Oxford
Plasmodium Falciparum Malaria (Uncomplicated)
A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.
A partially blinded randomised controlled non-inferiority trial comparing the efficacy, tolerability and safety of Triple ACTs artemether-lumefantrine+amodiaquine (AL+AQ) and artesunate-mefloquine+piperaquine (ASMQ+PPQ) and the…
- Trial name
- DeTACT-Africa (NCT03923725)
- Testing
- Artemether-lumefantrine+ Amodiaquine (AL+AQ), Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)
- Where
- 8 sites in Burkina Faso, Democratic Republic of the Congo and 6 more
- Volunteers
- 2,583 people
- Sponsor
- University of Oxford
Rabies
A Phase Ib/II Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG
This is a Phase Ib/II, open-label, head-to-head, age de-escalation dose-escalation, partially randomized trial to study the safety and immunogenicity of the candidate rabies vaccine ChAdOx2 RabG in healthy adults (age 18-45…
- Trial name
- NCT04270838
- Testing
- ChAdOx2 RabG, Inactivated Rabies Vaccine
- Where
- Tanzania
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Uncomplicated Plasmodium Falciparum Malaria
A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines
The goal of this open-label randomised, controlled, non-inferiority trial is to assess and compare the efficacy, tolerability and safety of a fixed dose TACT artemether-lumefantrine-amodiaquine (ALAQ) to the ACTs…
- Trial name
- FD-TACT (NCT05951595)
- Testing
- Artemether-Lumefantrine-Amodiaquine (ALAQ), Artemether-Lumefantrine (AL), Artesunate-Amodiaquine (ASAQ)
- Where
- Rwanda
- Volunteers
- 1,680 people
- Sponsor
- University of Oxford
Type1 Diabetes
Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)
The main purpose of this study is to see if a drug called aldesleukin, can preserve insulin production in children and young adults recently diagnosed with type 1 diabetes.
- Trial name
- ITAD (NCT03782636)
- Testing
- Aldesleukin
- Where
- 5 sites in United Kingdom
- Volunteers
- 41 people
- Sponsor
- University of Oxford
Respiratory Disease, Children, Only
Kinshasa Lung Ultrasound Approach Validation
Study team will perform a prospective, observational study in two sites in the Democratic Republic of Congo (DRC) and Bangladesh in children aged 3 months to 14 years, admitted to hospital with acute respiratory symptoms.
- Trial name
- K-LUS (NCT06839963)
- Where
- 3 sites in Bangladesh, Democratic Republic of the Congo and 1 more
- Volunteers
- 178 people
- Sponsor
- University of Oxford
Type 1 Diabetes (T1D), Registry
UK Islet Autoantibody Registry
Type 1 diabetes (T1D) is a life-long condition where the immune system destroys part of the body (the pancreas) which makes the chemical, insulin. Insulin is needed to control blood sugar levels.
- Conditions
- Type 1 Diabetes (T1D), Registry, Pre-diabetes, Screening
- Trial name
- UKIAb Registry (NCT07125365)
- Where
- United Kingdom
- Volunteers
- 350 people
- Sponsor
- University of Oxford
Malaria,Falciparum
Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso
This is a double blind randomised controlled clinical trial to evaluate the efficacy of R21 adjuvanted with Matrix-M in healthy 5-17 month old children in a malaria endemic area.
- Trial name
- NCT03896724
- Testing
- R21 adjuvanted with 25mcg Matrix-M, Rabies Vaccine, R21 adjuvanted with 50mcg Matrix-M
- Where
- Burkina Faso
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Emotional Processing
Losartan and Emotional Processing in Young People
This study explores the effects of single-dose losartan (50mg) versus placebo on emotional processing in young healthy volunteers.
- Trial name
- NCT06636812
- Testing
- Losartan potassium
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Obsessive Compulsive Disorder (OCD), CBT
Brief Cognitive Behaviour Therapy (CBT) for Adolescent OCD in Routine Clinical Practice
Obsessive-Compulsive Disorder (OCD) is a common and often disabling condition in young people, characterised by distressing, intrusive thoughts, images or urges, and repetitive behaviours intended to reduce discomfort or prevent…
- Trial name
- NCT06983301
- Testing
- Brief Cognitive Behavioural Therapy (CBT) for OCD
- Where
- 3 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- University of Oxford
Multiple Sclerosis
Metabolic Imaging of Neurological Disease
Multiple Sclerosis is a chronic condition that shows changes in the way that the brain consumes sugar. It is also known that there are a number of metabolic and inflammatory sequelae following a transient ischemic attack/stroke…
- Trial name
- MIND (NCT06900244)
- Where
- United Kingdom
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Serogroup C Meningococcal Meningitis, Diphtheria
Sero-epidemiological Survey of England in 2019/2020 - COVID-19
This is a pilot study to assess the feasibility of establishing a national sero-epidemiological survey in England in individuals aged 0-24 years, focusing on assessing humoral immunity against diphtheria, Group C invasive…
- Conditions
- Serogroup C Meningococcal Meningitis, Diphtheria, COVID-19
- Trial name
- STORY (NCT04061382)
- Testing
- Venepuncture, Oral fluid swab
- Where
- United Kingdom
- Volunteers
- 2,963 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Febrile Illness
Village Malaria Worker Expansion
This project will conduct pragmatic operational research in rural communities served by approximately 12 health centres and 120 village malaria workers in Battambang/Pailin, western Cambodia.
- Trial name
- CAM-VMW (NCT05045547)
- Where
- Cambodia
- Volunteers
- 7,191 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plague, Bubonic, Plague, Pneumonic
Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague
The primary objective of this trial is to test the hypothesis that ciprofloxacin monotherapy given (orally, intravenously, or combination) for 10 days is non-inferior to an aminoglycoside (given on days 1-3) followed by…
- Trial name
- IMASOY (NCT04110340)
- Testing
- Ciprofloxacin, Streptomycin, Gentamicin
- Where
- Madagascar
- Volunteers
- 222 people
- Sponsor
- University of Oxford
Pre-cancerous Lymphoproliferative Disorders
Oxford Pre-cancerous Lymphoproliferative Disorders Study
OxPLoreD is an observational cohort study to identify clinical, genomic and immunological predictive markers of progression to malignant disease.
- Trial name
- OxPLoreD (NCT04023747)
- Where
- 17 sites in United Kingdom
- Volunteers
- 574 people
- Sponsor
- University of Oxford
Malaria,Falciparum
Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.
A phase Ib age de-escalation and dose escalation open label clinical trial of the safety, immunogenicity and ex-vivo efficacy of a candidate malaria vaccine Pfs25-IMX313/Matrix-M administered intramuscularly in healthy adults and…
- Trial name
- NCT04271306
- Testing
- Pfs25-IMX313 (10ug)/Matrix-M (50ug), Pfs25-IMX313 (50ug)/Matrix-M (50ug), Pfs25-IMX313 (50ug)/Matrix-M (50ug) & Pfs25-IMX313 (10ug)/Matrix-M (50ug)
- Where
- Tanzania
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria,Falciparum
Safety and Immunogenicity of RH5.1/Matrix-M in Adults and Infants Living in Tanzania
This is an age de-escalation, dose-escalation open label randomised trial studying the safety and immunogenicity of RH5.1/Matrix-M, administered intramuscularly in healthy adults, young children and infants in Tanzania
- Trial name
- NCT04318002
- Testing
- RH5.1/Matrix-M
- Where
- Tanzania
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Chronic Pain
Distress in Adolescents With Chronic Pain: Who is at Risk, When, and Why
Living with chronic pain can be tough for any young person. But while some young people may experience distressing thoughts, others may not. No young person should face these problems alone.
- Trial name
- NCT06619171
- Where
- 2 sites in United Kingdom
- Volunteers
- 70 people
- Sponsor
- University of Oxford
Measles
Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings
This is a phase IIb clinical trial investigating the non-inferiority of immune responses in children given two doses of measles vaccine at different timepoints.
- Trial name
- BoostMe (NCT06667206)
- Testing
- Licenced Measles-Rubella vaccine
- Where
- Uganda
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- University of Oxford